Loading video...

Video Failed to Load

Go Home

Could a structured exercise program after undergoing adjuvant chemotherapy for colon cancer improve survival and quality of life? The latest video in our partnership with Dr. Glaucomflecken summarizes new research. Access the article for free:

NEJM's profile picture

NEJM

977,438 subscribers

71,403 views • 9 months ago •via X (Twitter)

Health & WellnessScience & TechnologyEducation
LIVE

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Our partnership with Dr. Glaucomflecken continues as he summarizes new research into fracture prevention with infrequent zoledronate in women 50 to 60 years of age. Access the article for free:
1:19

Our partnership with Dr. Glaucomflecken continues as he summarizes new research into fracture prevention with infrequent zoledronate in women 50 to 60 years of age. Access the article for free:

NEJM

62,459 views • 1 year ago

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:
1:22

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:

NEJM

130,538 views • 1 year ago

Our partnership with Dr. Glaucomflecken continues as he summarizes recent research into male-partner treatment to prevent recurrence of bacterial vaginosis. Access the article for free:
1:21

Our partnership with Dr. Glaucomflecken continues as he summarizes recent research into male-partner treatment to prevent recurrence of bacterial vaginosis. Access the article for free:

NEJM

58,510 views • 1 year ago

Patients with giant-cell arteritis need better treatments. This video, in partnership with Dr. Glaucomflecken, summarizes new research findings on the JAK-1 inhibitor upadacitinib in patients with giant-cell arteritis. Access the article for free:
1:28

Patients with giant-cell arteritis need better treatments. This video, in partnership with Dr. Glaucomflecken, summarizes new research findings on the JAK-1 inhibitor upadacitinib in patients with giant-cell arteritis. Access the article for free:

NEJM

92,811 views • 10 months ago

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:
1:24

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

NEJM

50,295 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken explores recent research into the safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite. Get free access to the article: #IDTwitter
1:47

Our latest video in our partnership with Dr. Glaucomflecken explores recent research into the safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite. Get free access to the article: #IDTwitter

NEJM

28,105 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:
1:14

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

NEJM

19,398 views • 6 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:
1:17

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:

NEJM

33,682 views • 1 month ago

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:
1:39

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:

NEJM

92,472 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:
1:23

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:

NEJM

37,322 views • 2 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology
1:23

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

NEJM

56,370 views • 4 months ago

Plague is a high-consequence infectious disease with epidemic potential. The latest video in our partnership with Dr. Glaucomflecken summarizes new research evaluating ciprofloxacin versus aminoglycoside–ciprofloxacin for bubonic plague in Madagascar. 👉
1:24

Plague is a high-consequence infectious disease with epidemic potential. The latest video in our partnership with Dr. Glaucomflecken summarizes new research evaluating ciprofloxacin versus aminoglycoside–ciprofloxacin for bubonic plague in Madagascar. 👉

NEJM

44,832 views • 8 months ago

Our partnership with Dr. Glaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free:
1:38

Our partnership with Dr. Glaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free:

NEJM

93,163 views • 1 year ago

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:
1:28

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

NEJM

88,397 views • 1 year ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the final analysis of 23 years of follow-up to evaluate the long-term effects of PSA screening. Read the full analysis for free:
1:16

Our latest video in our partnership with Dr. Glaucomflecken summarizes the final analysis of 23 years of follow-up to evaluate the long-term effects of PSA screening. Read the full analysis for free:

NEJM

185,143 views • 6 months ago

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:
1:46

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,730 views • 11 months ago

“Ah, it's your first gastroenteritis. It gets easier.” The latest video in our partnership with Dr. Glaucomflecken summarizes recent research on the effects of ondansetron after emergency visits in children with gastroenteritis-associated vomiting. 👉
1:08

“Ah, it's your first gastroenteritis. It gets easier.” The latest video in our partnership with Dr. Glaucomflecken summarizes recent research on the effects of ondansetron after emergency visits in children with gastroenteritis-associated vomiting. 👉

NEJM

43,226 views • 7 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:
1:27

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

NEJM

89,732 views • 4 months ago

Our latest video in our partnership with Dr. Glaucomflecken summarizes the CORALreef Lipids trial, which assessed the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period. Read the full study for free: #cardiology
1:18

Our latest video in our partnership with Dr. Glaucomflecken summarizes the CORALreef Lipids trial, which assessed the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels over a 52-week period. Read the full study for free: #cardiology

NEJM

56,231 views • 2 months ago

Which is better? Lactated Ringer’s solution or normal saline? The latest video in our partnership with Dr. Glaucomflecken summarizes the FLUID trial. 👉
1:27

Which is better? Lactated Ringer’s solution or normal saline? The latest video in our partnership with Dr. Glaucomflecken summarizes the FLUID trial. 👉

NEJM

87,299 views • 8 months ago